CHIP in Endothelial Dysfunction Associated With HEpEF (NCT05828888) | Clinical Trial Compass
UnknownNot Applicable
CHIP in Endothelial Dysfunction Associated With HEpEF
80 participantsStarted 2023-05-01
Plain-language summary
This study aims at identifying processes that are deregulated in blood cells by Clonal Hematopoiesis of Indeterminate Potential (CHIP) which are involved in the development of heart failure with preserved ejection fraction (HEpEF).
Who can participate
Age range
50 Years – 85 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* HFpEF group and control group
* male or female
* 50 ≤ age ≤ 85 ans
* Absence of evidence of hematological malignancy (known or obvious by the results of blood counts)
* Subject registered with a social security scheme
* Written informed consent obtained
* HFpEF group
* patients with a diagnosis of HFpEF according to the criteria defined by the European society of cardiology
* Control group
* patients with a neuro-cardiovascular pathology without any link to coronaropathy nor heart failure
Exclusion Criteria:
* Hematological malignancy (known or obvious on the results of blood counts)
* Chronic inflammatory disease (cancer, vasculitis, rheumatism, hepato-gastro-intestinal diseases)
* Long term anti-inflammatory treatments:
* Corticoids
* Nonsteroidal anti-inflammatory drugs
* Aspirin (\> 325 mg per day)
* Cyclo-oxygenase II inhibitors
* Persons under judicial safeguards, trustee or curatorship
* Person deprived of judicial or administrative freedom
* Person unable to give her consent
* Non-cooperative person
* Exclusion period after another clinical study or participation to another interventional clinical study testing a drug in the 30 days before inclusion
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Presence of clonal hematopoiesis indeterminate potential (CHIP)